Use access key #2 to skip to page content.

IBDvalueinvestin (98.50)

OPXA in discussions on partnership for its MS DRUG



January 06, 2011 – Comments (0) | RELATED TICKERS: OPXA , XOMA , DNDNQ

Based on what XOMA just recently got on a partnership, I see OPXA getting a similar type deal because the MS Drug has such a large market in the multi-billions on yearly sales with only a handful of companies splitting the sales.

CEO of OPXA wrote in a letter to shareholders: We remain engaged in discussions with potential industry partners concerning the Tovaxin opportunity.


XOMA XOMA Limited target raised to $16 at Ladenburg Thalmann following partnership for XOMA-052 (6.67 )

Ladenburg Thalmann raises their XOMA tgt to $16 from $12. Servier's Development and Commercialization Agreement with XOMA for XOMA-052 consists of $35 mln in upfront cash and approx €355 ($470) mln in future development and commercial milestones for multiple indications and tiered royalties (from mid-single digit to mid-teens) on sales. Development of XOMA-052 for cardiovascular and diabetes indications are fully funded by Servier. Of note, although Servier will have worldwide rights to XOMA-052 for diabetes and cardiovascular indications, XOMA has the option to reacquire U.S. and Japanese rights to XOMA-052 for these indications.  

0 Comments – Post Your Own

Featured Broker Partners